Metformin for Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Registration Number
- NL-OMON25659
- Lead Sponsor
- ZonMw
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 62
•Age =18 years at baseline
•A diagnosis of HS for at least 1 year prior to baseline
•mild to moderately active disease defined by a HS Physician Global Assessment (HS-PGA) score of 2-3 and the Refined Hurley classification of mild to moderate at baseline
•Indication for systemic therapy; i.e. uncontrolled disease under conventional topical therapy.
•Able and willing to give written informed consent and to comply with the study requirements
•Pregnant and lactating women
•Concomitant diabetes mellitus
•Use of antibiotics within 14 days prior to baseline
•Use of immunosuppressing/modulating therapies within 28 days prior to baseline
•A known allergy to metformin or doxycycline or any of the ingredients metformin or doxycycline
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method